Cempra Inc (CEMP) 34.31 $CEMP
Pharma Stocks Technical Review -- Novo Nordisk, Mallinckrodt, Theravance, Cempra, and Ampio Pharma
PR Newswire - Fri Mar 27, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MNK: 126.65 (-3.48), NVO: 53.39 (-1.29), THRXV: 28.00 (+7.07), AMPE: 7.53 (+0.10), CEMP: 34.31 (-0.62), THRX: 15.72 (-0.88)
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SAGE: 50.23 (-0.83), SONC: 31.70 (-0.59), GLMD: 9.42 (-0.31), NVAX: 8.27 (-0.37), ORMP: 6.37 (-0.01), AFMD: 6.30 (+0.16), SONS: 7.88 (-0.08), CEMP: 34.31 (-0.62), VBLT: 5.20 (-0.09), ROVI: 18.21 (-0.63), CECO: 5.03 (-0.22)
Cempra (CEMP) Showing Signs Of A Dead Cat Bounce Today
at The Street - Tue Mar 24, 10:07AM CDT
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 34.31 (-0.62)
Cempra: Reviving The Antibiotic Market
DoconStocks - at Seeking Alpha - Tue Mar 24, 9:59AM CDT
CEMP: 34.31 (-0.62)
Cempra to Participate in Jefferies 2015 Antibiotic Summit Investor Conference
GlobeNewswire - Mon Mar 16, 4:21PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2015 Antibiotic Summit meeting for investors. Prabhavathi Fernandes, Ph.D., chief executive officer and David Moore, chief commercial officer of Cempra, will provide a company overview and update on the company's clinical programs. The summit will be held on Wednesday, March 18, 2015 in New York. The agenda for the one-day program consists of panel discussions led by infectious disease physician specialists and cost reimbursement experts, as well as one-on-one investor and group meetings.
CEMP: 34.31 (-0.62)
Critical Alerts For GoPro, BlackBerry, GW Pharmaceuticals, Cempra, Anacor Pharmaceuticals, TG Therapeutics, Whiting Petroleum, Travelers, Automatic Data Processing and AOL Released By InvestorsObserver
PR Newswire - Mon Mar 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, BBRY, GWPH, CEMP, ANAC, TGTX, WLL, TRV, ADP and AOL.
GPRO: 43.41 (-0.17), WLL: 30.90 (+0.18), ADP: 85.64 (-0.25), GWPH: 91.13 (+2.73), AOL: 39.61 (+0.18), BBRY: 8.93 (+0.13), TGTX: 15.48 (-0.68), ANAC: 57.85 (+1.04), CEMP: 34.31 (-0.62), TRV: 108.13 (-1.51)
Cempra's (CEMP) CEO Dr. Prabha Fernandes on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 6:39PM CST
CEMP: 34.31 (-0.62)
Cempra reports 4Q loss
Automated Insights - Wed Feb 25, 3:52PM CST
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Wednesday reported a loss of $16.9 million in its fourth quarter.
CEMP: 34.31 (-0.62)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 115.92 (+0.93), CSGP: 197.83 (+0.18), HK: 1.54 (-0.04), GPOR: 45.91 (-0.27), BLDP: 2.10 (+0.08), PRSS: 3.89 (+0.16), EAC: 4.32 (-0.11), GXP: 26.68 (+0.20), DXCM: 62.34 (+0.36), LHCG: 33.03 (+0.55), STAA: 7.43 (-0.08), ESRT: 18.81 (-0.10), PGTI: 11.17 (-0.06), ORIG: 6.59 (+0.04), CWT: 24.51 (-0.30), MCHX: 4.08 (-0.17), RGR: 49.63 (+0.22), CLUB: 6.81 (-0.06), MMLP: 35.44 (+0.80), AR: 35.32 (+0.11), IL: 10.34 (-0.13), FOE: 12.55 (-0.09), ARI: 17.18 (+0.08), ANIK: 41.17 (-0.06), FARO: 62.13 (+2.37), BWC: 32.09 (+0.29), ESV: 21.07 (-0.05), MELI: 122.52 (+0.85), EPAM: 61.29 (-0.94), OAS: 14.22 (+0.05), AWR: 39.89 (+0.04), BMRN: 124.62 (-4.51), SFM: 35.23 (+1.68), ELGX: 17.07 (+0.24), AEGN: 18.05 (-0.20), AREX: 6.59 (-0.19), MDVN: 129.07 (-4.87), AGO: 26.39 (+0.33), RIG: 14.67 (-0.04), GMED: 25.24 (+0.38), DRYS: 0.76 (-0.05), AMSG: 61.52 (-0.91), LGCY: 10.12 (-0.11), CHDN: 114.97 (+0.84), KW: 26.14 (-0.09), PVA: 6.48 (-0.28), PLKI: 59.82 (-0.92), RIGP: 12.25 (-0.67), LB: 94.29 (+0.09), CLVS: 74.23 (-0.72), SBY: 16.16 (+0.06), CEMP: 34.31 (-0.62), CHMT: 27.29 (+0.04), AVGO: 126.98 (-3.57), CRM: 66.81 (-0.04), EHTH: 9.38 (-0.31)
'Fast Money' Recap: Focus Shifts to Russia as Greece Drama Ebbs
at The Street - Sat Feb 21, 4:00AM CST
The trading panel discussed Greece, Russia, gold and whether Apple will ever produce a car.
FEZ: 38.82 (-0.56), FEYE: 39.25 (-0.78), FB: 82.21 (-0.98), GM: 37.50 (-0.18), RSX: 17.03 (-0.21), IWM: 124.37 (-0.40), CEMP: 34.31 (-0.62), TWTR: 50.08 (+0.19), GDX: 18.24 (-0.23), PANW: 146.08 (-2.53), AAPL: 124.43 (-1.94), CSCO: 27.52 (-0.13)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 53.39 (-1.29), THRXV: 28.00 (+7.07), AMPE: 7.53 (+0.10), CEMP: 34.31 (-0.62), THRX: 15.72 (-0.88), XNPT: 7.12 (-0.14)
Cempra to Report Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Feb 17, 7:01AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on February 25, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EST that day to discuss the financial results and provide a corporate update.
CEMP: 34.31 (-0.62)
Retirement Planning - Cramer's Mad Money (2/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 09, 6:48AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, February 6. This earnings season has been a vast disappointment. Cramer believes that terrible earnings now is good, as it sets the bar really low for the year....
WFM: 52.08 (-0.27), TSLA: 188.77 (-1.80), HAL: 43.88 (+0.06), VFC: 75.31 (+0.18), MAS: 26.70 (+0.25), VTR: 73.02 (-0.63), PEP: 95.62 (-0.90), WWAV: 44.34 (-0.30), DNB: 128.36 (-0.82), CVS: 103.21 (-0.62), CEMP: 34.31 (-0.62), REGN: 451.48 (-8.30), CSCO: 27.52 (-0.13), BHI: 63.58 (+0.10)
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue Feb 03, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 34.31 (-0.62)
Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jan 16, 8:54AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 34.31 (-0.62)
Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock
GlobeNewswire - Tue Jan 13, 3:01PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 5,250,000 shares of common stock, plus an additional 787,500 shares issued pursuant to the full exercise by the underwriters of their option to purchase additional shares at a public offering price of $24.50 per share. The full exercise of the option increases the net proceeds to the company, after underwriting discounts and commissions and expected expenses of the offering expenses, from approximately $120.6 million to approximately $138.7 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses.
CEMP: 34.31 (-0.62), MS: 35.69 (-0.62)
Cempra Has Insider Interest And A Blockbuster Anti-Biotic: Buy
Value Insight - at Seeking Alpha - Tue Jan 13, 7:55AM CST
JNJ: 100.60 (-0.95), CEMP: 34.31 (-0.62), SNY: 49.44 (-0.80)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), PFE: 34.79 (-0.21), INCY: 91.66 (-2.53), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26), ALKS: 60.97 (-1.55), CELG: 115.28 (-4.74), AGEN: 5.13 (-0.03), JNJ: 100.60 (-0.95), NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38), ISIS: 63.67 (-1.14), ALNY: 104.42 (-3.36), KITE: 57.68 (-2.30), GILD: 98.13 (-2.56), GWPH: 91.13 (+2.73), INFI: 13.98 (-0.34), ABBV: 58.54 (+0.30), CEMP: 34.31 (-0.62), SNY: 49.44 (-0.80), ARNA: 4.37 (-0.11), REGN: 451.48 (-8.30), NVS: 98.61 (-2.70)
Pharma Stocks Technical Review -- Novo Nordisk, Mallinckrodt, Theravance, Cempra, and Ampio Pharma
PR Newswire - Fri Mar 27, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
MNK: 126.65 (-3.48), NVO: 53.39 (-1.29), THRXV: 28.00 (+7.07), AMPE: 7.53 (+0.10), CEMP: 34.31 (-0.62), THRX: 15.72 (-0.88)
Nasdaq stocks posting largest percentage decreases
AP - Wed Mar 25, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
SAGE: 50.23 (-0.83), SONC: 31.70 (-0.59), GLMD: 9.42 (-0.31), NVAX: 8.27 (-0.37), ORMP: 6.37 (-0.01), AFMD: 6.30 (+0.16), SONS: 7.88 (-0.08), CEMP: 34.31 (-0.62), VBLT: 5.20 (-0.09), ROVI: 18.21 (-0.63), CECO: 5.03 (-0.22)
Cempra (CEMP) Showing Signs Of A Dead Cat Bounce Today
at The Street - Tue Mar 24, 10:07AM CDT
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 34.31 (-0.62)
Cempra: Reviving The Antibiotic Market
DoconStocks - at Seeking Alpha - Tue Mar 24, 9:59AM CDT
CEMP: 34.31 (-0.62)
Cempra to Participate in Jefferies 2015 Antibiotic Summit Investor Conference
GlobeNewswire - Mon Mar 16, 4:21PM CDT
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Jefferies 2015 Antibiotic Summit meeting for investors. Prabhavathi Fernandes, Ph.D., chief executive officer and David Moore, chief commercial officer of Cempra, will provide a company overview and update on the company's clinical programs. The summit will be held on Wednesday, March 18, 2015 in New York. The agenda for the one-day program consists of panel discussions led by infectious disease physician specialists and cost reimbursement experts, as well as one-on-one investor and group meetings.
CEMP: 34.31 (-0.62)
Critical Alerts For GoPro, BlackBerry, GW Pharmaceuticals, Cempra, Anacor Pharmaceuticals, TG Therapeutics, Whiting Petroleum, Travelers, Automatic Data Processing and AOL Released By InvestorsObserver
PR Newswire - Mon Mar 16, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GPRO, BBRY, GWPH, CEMP, ANAC, TGTX, WLL, TRV, ADP and AOL.
GPRO: 43.41 (-0.17), WLL: 30.90 (+0.18), ADP: 85.64 (-0.25), GWPH: 91.13 (+2.73), AOL: 39.61 (+0.18), BBRY: 8.93 (+0.13), TGTX: 15.48 (-0.68), ANAC: 57.85 (+1.04), CEMP: 34.31 (-0.62), TRV: 108.13 (-1.51)
Cempra's (CEMP) CEO Dr. Prabha Fernandes on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 25, 6:39PM CST
CEMP: 34.31 (-0.62)
Cempra reports 4Q loss
Automated Insights - Wed Feb 25, 3:52PM CST
CHAPEL HILL, N.C. (AP) _ Cempra Inc. (CEMP) on Wednesday reported a loss of $16.9 million in its fourth quarter.
CEMP: 34.31 (-0.62)
Notable earnings after Wednesday's close
Seeking Alpha - at Seeking Alpha - Tue Feb 24, 4:35PM CST
CXO: 115.92 (+0.93), CSGP: 197.83 (+0.18), HK: 1.54 (-0.04), GPOR: 45.91 (-0.27), BLDP: 2.10 (+0.08), PRSS: 3.89 (+0.16), EAC: 4.32 (-0.11), GXP: 26.68 (+0.20), DXCM: 62.34 (+0.36), LHCG: 33.03 (+0.55), STAA: 7.43 (-0.08), ESRT: 18.81 (-0.10), PGTI: 11.17 (-0.06), ORIG: 6.59 (+0.04), CWT: 24.51 (-0.30), MCHX: 4.08 (-0.17), RGR: 49.63 (+0.22), CLUB: 6.81 (-0.06), MMLP: 35.44 (+0.80), AR: 35.32 (+0.11), IL: 10.34 (-0.13), FOE: 12.55 (-0.09), ARI: 17.18 (+0.08), ANIK: 41.17 (-0.06), FARO: 62.13 (+2.37), BWC: 32.09 (+0.29), ESV: 21.07 (-0.05), MELI: 122.52 (+0.85), EPAM: 61.29 (-0.94), OAS: 14.22 (+0.05), AWR: 39.89 (+0.04), BMRN: 124.62 (-4.51), SFM: 35.23 (+1.68), ELGX: 17.07 (+0.24), AEGN: 18.05 (-0.20), AREX: 6.59 (-0.19), MDVN: 129.07 (-4.87), AGO: 26.39 (+0.33), RIG: 14.67 (-0.04), GMED: 25.24 (+0.38), DRYS: 0.76 (-0.05), AMSG: 61.52 (-0.91), LGCY: 10.12 (-0.11), CHDN: 114.97 (+0.84), KW: 26.14 (-0.09), PVA: 6.48 (-0.28), PLKI: 59.82 (-0.92), RIGP: 12.25 (-0.67), LB: 94.29 (+0.09), CLVS: 74.23 (-0.72), SBY: 16.16 (+0.06), CEMP: 34.31 (-0.62), CHMT: 27.29 (+0.04), AVGO: 126.98 (-3.57), CRM: 66.81 (-0.04), EHTH: 9.38 (-0.31)
'Fast Money' Recap: Focus Shifts to Russia as Greece Drama Ebbs
at The Street - Sat Feb 21, 4:00AM CST
The trading panel discussed Greece, Russia, gold and whether Apple will ever produce a car.
FEZ: 38.82 (-0.56), FEYE: 39.25 (-0.78), FB: 82.21 (-0.98), GM: 37.50 (-0.18), RSX: 17.03 (-0.21), IWM: 124.37 (-0.40), CEMP: 34.31 (-0.62), TWTR: 50.08 (+0.19), GDX: 18.24 (-0.23), PANW: 146.08 (-2.53), AAPL: 124.43 (-1.94), CSCO: 27.52 (-0.13)
Technical Report on Pharma Stocks -- Novo Nordisk, Theravance, XenoPort, Cempra, and Ampio Pharma
PR Newswire - Wed Feb 18, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NVO: 53.39 (-1.29), THRXV: 28.00 (+7.07), AMPE: 7.53 (+0.10), CEMP: 34.31 (-0.62), THRX: 15.72 (-0.88), XNPT: 7.12 (-0.14)
Cempra to Report Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Feb 17, 7:01AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it will report fourth quarter and full year 2014 financial results after the close of U.S. financial markets on February 25, 2015. Cempra management will host a webcast and conference call at 4:30 p.m. EST that day to discuss the financial results and provide a corporate update.
CEMP: 34.31 (-0.62)
Retirement Planning - Cramer's Mad Money (2/6/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Feb 09, 6:48AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, February 6. This earnings season has been a vast disappointment. Cramer believes that terrible earnings now is good, as it sets the bar really low for the year....
WFM: 52.08 (-0.27), TSLA: 188.77 (-1.80), HAL: 43.88 (+0.06), VFC: 75.31 (+0.18), MAS: 26.70 (+0.25), VTR: 73.02 (-0.63), PEP: 95.62 (-0.90), WWAV: 44.34 (-0.30), DNB: 128.36 (-0.82), CVS: 103.21 (-0.62), CEMP: 34.31 (-0.62), REGN: 451.48 (-8.30), CSCO: 27.52 (-0.13), BHI: 63.58 (+0.10)
Cempra to Present at Three Upcoming Investor Conferences
GlobeNewswire - Tue Feb 03, 7:00AM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in three upcoming investor conferences. Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will provide a company overview and update on its clinical development programs.
CEMP: 34.31 (-0.62)
Trade-Ideas: Cempra (CEMP) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Jan 16, 8:54AM CST
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
CEMP: 34.31 (-0.62)
Cempra Announces Full Exercise of Additional Share Option and Completion of the Public Offering of Common Stock
GlobeNewswire - Tue Jan 13, 3:01PM CST
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 5,250,000 shares of common stock, plus an additional 787,500 shares issued pursuant to the full exercise by the underwriters of their option to purchase additional shares at a public offering price of $24.50 per share. The full exercise of the option increases the net proceeds to the company, after underwriting discounts and commissions and expected expenses of the offering expenses, from approximately $120.6 million to approximately $138.7 million. The company intends to use the net proceeds from the offering to fund its research and development activities, including continued clinical and regulatory development of solithromycin in community acquired bacterial pneumonia (CABP) and gonorrhea and Taksta(TM) in bone and joint infections, preparation for commercial readiness for solithromycin in CABP, working capital and general corporate and administrative expenses.
CEMP: 34.31 (-0.62), MS: 35.69 (-0.62)
Cempra Has Insider Interest And A Blockbuster Anti-Biotic: Buy
Value Insight - at Seeking Alpha - Tue Jan 13, 7:55AM CST
JNJ: 100.60 (-0.95), CEMP: 34.31 (-0.62), SNY: 49.44 (-0.80)
Cancel JPMorgan! Plenty of Pre-Conference Data and Deals to Digest
Brian Orelli, The Motley Fool - Motley Fool - Sat Jan 10, 6:49AM CST
JPMorgan 's annual healthcare conference is set to kick off next week, but many companies already announced clinical trial data and deals ahead of the conference. Part of the early release has to do with SEC regulations. In addition to public...
BIIB: 422.24 (-9.38), VRTX: 117.97 (-3.28), PFE: 34.79 (-0.21), INCY: 91.66 (-2.53), AMGN: 159.85 (-4.45), BMY: 64.50 (-1.26), ALKS: 60.97 (-1.55), CELG: 115.28 (-4.74), AGEN: 5.13 (-0.03), JNJ: 100.60 (-0.95), NBIX: 39.71 (-1.82), JPM: 60.58 (-0.38), ISIS: 63.67 (-1.14), ALNY: 104.42 (-3.36), KITE: 57.68 (-2.30), GILD: 98.13 (-2.56), GWPH: 91.13 (+2.73), INFI: 13.98 (-0.34), ABBV: 58.54 (+0.30), CEMP: 34.31 (-0.62), SNY: 49.44 (-0.80), ARNA: 4.37 (-0.11), REGN: 451.48 (-8.30), NVS: 98.61 (-2.70)
